New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
07:06 EDTINCYIncyte upgraded to Buy from Neutral at Lazard Capital
Lazard Capital upgraded Incyte with a $25 price target citing increased penetration estimates for Jakafi in myelofibrosi.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
06:57 EDTINCYIncyte trial miss does not impact Jakafi assumptions, says Leerink
Subscribe for More Information
July 23, 2014
16:41 EDTINCYIncyte's Ruxolitinib shows no statistical significance in primary endpoint
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use